Pancreatic ductal adenocarcinoma (PDAC) has one of the highest incidence/death ratios
among all neoplasms due to its late diagnosis and dominant chemoresistance. Most PDAC …

Introduction: Pancreatic cancer is a complex disease, with an extremely poor response to
chemotherapy. Emerging evidence indicates that the tumor microenvironment (TME) might …

Pancreatic cancer (PDAC) is one of the deadliest types of human cancers, owing to late
stage at presentation and pervasive therapeutic resistance. The extensive tumour …

Pancreatic cancer (pancreatic ductal adenocarcinoma, PDA) is infamously moving to the top
of the list as one of the most lethal cancers with an overall 5 year survival rate of 7%. Multiple …

Simple Summary Pancreatic cancer is deadly cancer characterized by dense stroma
creating an immunosuppressive tumor microenvironment. Accumulating evidences indicate …

Resistance to therapy is one of the major factors that contribute to dismal survival statistics in
pancreatic cancer. While there are many tumor intrinsic and tumor microenvironment driven …

Pancreatic ductal adenocarcinoma (PDAC) incidence and related-deaths are increasing
worldwide. PDAC is characterized by poor prognosis due to late diagnosis, high metastatic …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal cancer with a dismal
five-year survival rate of 11%. Despite remarkable advancements in cancer therapeutics …

Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant
cancers, and current therapies targeting cancer-associated molecular pathways have not …